Document Detail


Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.
MedLine Citation:
PMID:  17119918     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM/HYPOTHESIS: To determine whether marine-derived n-3 polyunsaturated fatty acids (n-3 PUFA) (also known as omega-3 fatty acids) have beneficial effects on haematological and thrombogenic risk markers in addition to dyslipidaemia, in patients with type 2 diabetes. METHODS: A systematic review and meta-analysis of randomised controlled trials comparing dietary or non-dietary intake of n-3 PUFA with placebo in type 2 diabetes was conducted by systematically searching databases from 1966 to February 2006. Changes in C-reactive protein, IL-6, TNF-alpha, platelet function, fibrinogen, factor VII, von Willebrand factor, endothelial function, heart rate and blood pressure were recorded. Inclusion of studies, data extraction and quality were assessed independently in duplicate. RESULTS: Twelve trials involving 847 subjects with a mean treatment duration of 8.5 weeks included sufficient data to permit pooling. Compared with placebo, n-3 PUFA supplementation had a significant effect on two outcomes: reducing the level of diastolic blood pressure (five trials, 248 subjects) by a mean of 1.8 mm Hg (95% CI 0.0-3.6, p = 0.05) and increasing factor VII (two trials, 116 subjects) by 24.9% (95% CI 7.2-42.6, p = 0.006). There were no significant effects on systolic blood pressure, fibrinogen or heart rate. CONCLUSIONS/INTERPRETATION: These results suggest that, in addition to the recognised effects on dyslipidaemia, n-3 PUFA decreases diastolic blood pressure, and appears to increase factor VII. Larger and more rigorously conducted clinical trials are required to establish conclusively the role of n-3 PUFA in cardiovascular risk markers and clinical outcomes in type 2 diabetes.
Authors:
J Hartweg; A J Farmer; R R Holman; H A W Neil
Related Documents :
15184288 - Obesity is an important determinant of baseline serum c-reactive protein concentration ...
17243498 - Blood pressure response to exercise test and serum lipids in normotensive men with posi...
1381018 - Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
16789638 - Asymptomatic cardiomyopathy in children and adolescents with type 1 diabetes mellitus: ...
16321088 - Evanescent high pressure during hypersonic cluster-surface impact characterized by the ...
8489558 - Cardiotonic activity of the water soluble forskolin derivative 8,13-epoxy-6 beta-(piper...
Publication Detail:
Type:  Journal Article; Meta-Analysis     Date:  2006-11-21
Journal Detail:
Title:  Diabetologia     Volume:  50     ISSN:  0012-186X     ISO Abbreviation:  Diabetologia     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-08     Completed Date:  2007-09-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0006777     Medline TA:  Diabetologia     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  250-8     Citation Subset:  IM    
Affiliation:
Division of Public Health and Primary Health Care, University of Oxford, Oxford, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiotonic Agents
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic
Controlled Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications,  physiopathology*
Diabetic Angiopathies / prevention & control*
Fatty Acids, Omega-3 / therapeutic use*
Hematologic Diseases / prevention & control*
Humans
Placebos
Thrombosis / prevention & control
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Fatty Acids, Omega-3; 0/Placebos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching ...
Next Document:  Beta(2)-Adrenergic activation increases glycogen synthesis in L6 skeletal muscle cells through a sig...